Abbott announces two FDA clearances for life support system
April 26, 2023Medical Communications
US-based medical devices and healthcare company Abbott has announced two new clearances from the US Food and Drug Administration (FDA) …
MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases
April 25, 2023Business Services
London, United Kingdom, April 25, 2023 — MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target …
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
April 25, 2023Business Services
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded …
Brain scanning technology to be used for clinical psychedelics trials in pioneering London start-up partnership
April 25, 2023Business Services
London, UK: Commercial trials for psychedelics-assisted medical treatments will now have access to state-of-the-art brain scanning technology thanks to a …
Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference
April 25, 2023Business Services
Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to …
EMA validates marketing authorisation application for Jemperli with chemotherapy
April 25, 2023Medical Communications
GSK has announced that the European Medicines Agency (EMA) has validated the company’s Type II Variation for a new indication …
3B Pharmaceuticals and Novartis enter into licensing agreement for FAP-targeting technology
April 25, 2023Research and Development
German biotechnology company 3B Pharmaceuticals (3BP) and Switzerland-based Novartis have announced that they have entered into a Global Exclusive Licensing …
NICE publishes Final Appraisal Document for multiple myeloma drug
April 25, 2023Medical Communications
The National Institute for Health and Care Excellence (NICE) has submitted a Final Appraisal Document (FAD) for the use of …
AstraZeneca and Ionis share positive results from phase 3 trial for eplontersen
April 25, 2023Medical Communications
AstraZeneca and Ionis have announced positive results from their phase 3 NEURO-TTRansform trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy …
National Institute for Health and Care Excellence recommends Darzalex® (daratumumab) with bortezomib and dexamethasone for routine use on the NHS as treatment for multiple myeloma
April 24, 2023Business Services
High Wycombe, 24 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson are pleased to announce that the …
Sphere Fluidics begins work with partners on 3DSecret program to investigate mechanisms of metastasis in cancer
April 24, 2023Business Services
Cambridge, UK, 24th April 2023: Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, …
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
April 24, 2023Business Services
WILMINGTON, Del. – April 20, 2023 – Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing …
Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
April 24, 2023Business Services
BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission …
NICE gives green light to ibrutinib plus venetoclax as first-line treatment option for chronic lymphocytic leukaemia
April 24, 2023Business Services
High Wycombe, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson is pleased to announce that the …
NICE recommends treatment combination for advanced leukaemia
April 24, 2023Medical Communications
The National Institute for Health and Care Excellence (NICE) has recommended Janssen’s imbruvica (ibrutinib) alongside venetoclax as a treatment option …
Sanofi offers hepatitis A vaccine for UK children
April 24, 2023Medical Communications
Sanofi has introduced a hepatitis A vaccine for children aged between one to 15 years old in the UK. The …
AbbVie shares results from phase 3 trial for atogepant migraine treatment
April 24, 2023Research and Development
AbbVie has shared positive results from its phase 3 ELEVATE study, which assessed atogepant for the preventative treatment of episodic …
Aptar and Healint announce collaboration on CNS and immune system conditions management
April 24, 2023Medical Communications
AI healthcare company Healint and Software as a Medical Device (SaMD) expert Aptar Digital Health have announced a collaboration aiming …
RetinAI and Boehringer Ingelheim partner over AI treatments for geographic atrophy
April 21, 2023Medical Communications
Swiss data management software company RetinAI and US-based Boehringer Ingelheim have announced a partnership to improve patient outcomes in geographic …
FDA awards clearance to Meridian Bioscience for Curian Shiga Toxin assay
April 21, 2023Medical Communications
Meridian Bioscience, a US-based diagnostic testing solutions provider, has announced that the FDA has given clearance for its new Curian …
